SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-23-000095
Filing Date
2023-11-13
Accepted
2023-11-13 16:26:01
Documents
67
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q awh-20230930x10q.htm   iXBRL 10-Q 4163402
2 EX-31.1 awh-20230930xex31_1.htm EX-31.1 15273
3 EX-31.2 awh-20230930xex31_2.htm EX-31.2 16672
4 EX-32.1 awh-20230930xex32_1.htm EX-32.1 12330
  Complete submission text file 0000926617-23-000095.txt   18206563

Data Files

Seq Description Document Type Size
5 EX-101.SCH awh-20230930.xsd EX-101.SCH 55234
6 EX-101.CAL awh-20230930_cal.xml EX-101.CAL 54646
7 EX-101.DEF awh-20230930_def.xml EX-101.DEF 252566
8 EX-101.LAB awh-20230930_lab.xml EX-101.LAB 382693
9 EX-101.PRE awh-20230930_pre.xml EX-101.PRE 432004
61 EXTRACTED XBRL INSTANCE DOCUMENT awh-20230930x10q_htm.xml XML 5328265
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 231399193
SIC: 2835 In Vitro & In Vivo Diagnostic Substances